Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Amgen’s stock falls 4% as analysts say drug updates lag competitors
The biotech offered an update on two drugs in development, but analysts said they’re not as effective as existing treatments.
Amgen stock slides 5% as analysts weigh in on drug study results (update)
Amgen (NASDAQ:AMGN) shares were down 5% Wednesday, the day after the company reported Phase 3 results for its drugs rocatinlimab and Uplizna. Late Tuesday, Amgen (AMGN) released data from a Phase 3 study of rocatinlimab in the treatment of atopic dermatitis,
Amgen stock falls on lackluster drug data
Shares of Amgen (AMGN) are sliding after the biotech company posted disappointing results from two drug studies. Market Domination Hosts Julie Hyman and Josh Lipton break down the updates from Amgen's immunology and rare disease development pipeline and discuss how the drugmaker is stacking up to its competitors.
FierceBiotech
2d
Amgen reports first phase 3 win for $400M eczema drug, but Dupixent rivalry doubts remain
Amgen has shared (PDF) the first phase 3 data on its $400 million eczema drug, linking the | Amgen has shared the first phase ...
Zacks.com on MSN
3h
Amgen (AMGN) Ascends While Market Falls: Some Facts to Note
Amgen (AMGN) ended the recent trading session at $322.67, demonstrating a +1.12% swing from the preceding day's closing price. The stock's performance was ahead of the S&P 500's daily loss of 0.13%.
JD Supra
8h
Amgen Announces Third-party Data Breach Stemming from Incident at Sirva Relocation
On 4, 2024, Amgen, Inc. filed a notice of data breach with the Attorney General of Massachusetts after discovering that ...
FiercePharma
2d
With success in myasthenia gravis trial, Amgen's Uplizna looks set up to add new indication
As for Uplizna, Amgen said that it is initiating regulatory filing activities to set it up for approval to treat MG. Last ...
1d
Amgen: Pipeline Updates, Uplizna Performs And Rocatinlimab Underwhelms
Amgen's shares fell despite positive phase 3 results of rocatinlimab and Uplizna. It looks well-positioned for long-term ...
2d
Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market
Amgen reports mixed results from Phase 3 trials, with rocatinlimab showing moderate success in atopic dermatitis and Uplizna ...
3d
Amgen gets early win in Regeneron lawsuit over Eylea biosimilar
Regeneron cannot immediately block U.S. sales of rival Amgen's proposed copy of its blockbuster eye-care drug Eylea, a ...
3d
Amgen's muscular disorder drug meets main goal in late-stage study
Amgen said on Tuesday its experimental drug, rocatinlimab, met the main goals in a late stage study testing it as a treatment ...
2d
Amgen's Rocatinlimab Has Commercial Potential Despite Competitive Landscape, Says Goldman Sachs
Amgen releases Phase 3 trial data for rocatinlimab and Uplizna, with analysts projecting strong sales despite competition in ...
7d
Where Will Amgen Be in 5 Years?
Beyond MariTide, Amgen has a rich pipeline with more than 30 phase 3 programs. Some are for existing medicines seeking label ...
3d
Amgen stock slips 3% following Phase 3 data for rocatinlimab, Uplizna (update)
Amgen (AMGN) shares slipped 3% in post-market trading after it reported Phase 3 data for two of its drugs, Uplizna and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Rocatinlimab
Uplizna
Regeneron
S&P 500 Index
NASDAQ
Feedback